American Chemical Society
Division of Medicinal Chemistry
New York City, NY, United States June 26-29, 2022
Registration
Introduction by Session Chair
Integrating DNA-Encoded Library Technologies in Lead Discovery (IL01)
Discovery of IRAKIMiDs: Dual-Mechanism Degraders Targeting IRAK4 and IMiD Substrates for Oncology (IL02)
Development and Optimization of Small Molecule RNA Degraders (IL03)
Coffee Break & Exhibition
Oral Peptides: Theory and Practice (IL04)
Structural Approach to Identify Lead Scaffolds for Protein-Protein Interaction Targets (IL05)
Poster Session (posters with odd numbers)
Chaired by
Welcome Reception & Networking
End of the Day
Introduction by Session Chairs
M3541 and M4076: Discovery and Optimization of Potent and Selective ATM Kinase Inhibitors with Strong Anti-tumor Efficacy in Combination Therapies (IL06)
Discovery and Validation of in vitro and in vivo Probes for Human DNA Polymerase Theta (Polθ) (IL07)
The Modification of Pyrazolopyrimidinones and their Effect on WEE1 Inhibition and the DNA Damage Response (IL08)
Coffee Break & Exhibition
Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9/cyclin T1 for MYC-dependent Cancers (IL09)
Harnessing CDK12 Inhibition of Transcriptional Machinery to Induce Dimerization between DDB1 and CDK12-cyclinK Complex for Targeted Protein Degradation (IL10)
Lunch & Exhibition until 1:15 PM
Sponsored by ACS Publications
Optional Schrödinger Workshop - Augmenting Medicinal Chemistry with Digital Chemistry: A CDK2 Inhibitor Design Challenge
Introduction by Session Chairs
Rational Design of Inhibitors of Protein-Protein Interactions (IL11)
Optimization of Mycobacterium Tuberculosis (Mtb) Selective Inhibitors of Lipoamide Dehydrogenase (Lpd) (IL13)
Coffee Break & Exhibition
Therapeutic Potential of the Gut-Brain Axis (IL14)
Designing and Combining Cancer's Off Switches (IL15)
End of Session 3
Optional Iktos Workshop - AI Tools for Medicinal Chemists: Novel Compound Design and Retrosynthesis Prediction
Poster Session 2 (posters with even numbers)
Chaired by
End of the Day
Introduction by Session Chairs
Unraveling Autophagy in Cancer Using Chemical Genetics (IL16)
Small Molecule PINK1 Activators Rescue Parkinson’s Disease Pathology (IL17)
Revolutionizing Discovery and Development of ALS Therapeutics using Transformational, AI-powered 'All-in-Human' Platforms (IL18)
Coffee Break & Exhibition
Chasing Challenging Targets: Development of Selective Inhibitors of the Autophagy Pathway to Impact Cancer Therapy (IL19)
Chemical Activation of Chaperone-Mediated Autophagy for Protection against Neurodegeneration (IL20)
Necessary Complexity: The Discovery of Selective, CNS Penetrant LRRK2 Inhibitors for the Treatment of Parkinson’s Disease (IL21)
End of AM Program
Social Activities & Free Time
Award Dinner
Award Session - Opening Address
Award Ceremony chaired by ACS Medi Division Chair 2022, Prof. Amanda Bryant-Friedrich (Wayne State University, United States)
2022 Division of Medicinal Chemistry Award Lecture
A Perspective on the Arc of Innovation in Drug Discovery over Three Decades (AL01)
Prize Ceremony chaired by Dr Janos Eles (Gedeon Richter, Hungary)
2022 IUPAC-Richter Prize Lecture
Drug Discovery in Academia: Some Success Stories (AL02)
End of the Day
Introduction by Session Chair
Discovery of LPA1 antagonists for the treatment of Pulmonary Fibrotic Diseases (IL22)
Discovery of Risdiplam, a Medicine for the Treatment of Spinal Muscular Atrophy (IL23)
The Invention of MK-8262, a CETP Inhibitor for the Treatment of Coronary Heart Disease (IL24)
Coffee Break & Exhibition
Discovery of Inavolisib, a Highly Selective Inhibitor of PI3K-α that Induces Degradation of Mutant-p110α Protein (IL25)
Discovery of PF-07081532: a Small Molecule GLP-1 Receptor Agonist Suitable for Once-daily Oral Administration (IL26)
Discovery of LY3154885, a Second Generation Human Dopamine D1 Receptor Positive Allosteric Modulator with an Improved Drug-Drug Interaction Risk Profile (IL27)
Lunch Break & Exhibition until 1:20PM
Sponsored by Paraza Pharma
Optional Aseda Sciences Workshop - Drug Discovery Platforms, the Predictive Information Gap, and How to Bridge it
Introduction by Session Chair
Small Molecule Drug Discovery in Academia: DYRK1A Inhibitors as Novel beta-Cell Regenerative Drugs for Diabetes (IL28)
Discovery of Upadacitinib: a Tricyclic Janus Kinase 1 (JAK1) Inhibitor (IL29)
Anticancer Drug Discovery from Pets to People, the Story of PAC-1 (IL30)
Coffee Break & Exhibition
Discovery of Nix-TB as a Novel Regimen that Significantly Shortens Treatment of Tuberculosis (IL31)
Closing Remarks
Departure